Announced Fri, 14 Aug · 12:46 IST
Sudarshan Pharma shares presentation on proposed USFDA plant acquisition
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.1%1-day move
₹36.00
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-1.1+3.8+2.8+6.3+6.1—————
Up moveDown movePending
AI summary
Sudarshan Pharma filed an updated presentation on its proposed acquisition of a USFDA-approved API manufacturing plant near Visakhapatnam. The 14-acre facility has 4 production blocks with 584 KL total capacity, 200 employees, and approvals from USFDA (2024), WHO Geneva (2024), and ANVISA (2025). It makes APIs and intermediates for antiretrovirals, antifungals, and other drugs. Major customers include Laurus Labs, Cipla, Dr. Reddy's, and Mylan.
Likely market impact
Positive: brings a USFDA-approved API plant with reputed pharma clients. Watch for deal completion and valuation.